We are live on
!
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
+9.9%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.89B
AUM Growth
+$159M
(+9.2%)
Cap. Flow
+$27.9M
Cap. Flow
% of AUM
1.48%
Top 10 Holdings %
Top 10 Hldgs %
34.09%
Holding
355
New
45
Increased
117
Reduced
138
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Capital One
COF
|
+$36.2M |
| 2 |
West Pharmaceutical
WST
|
+$24.3M |
| 3 |
Envista
NVST
|
+$23.9M |
| 4 |
JPMorgan Chase
JPM
|
+$22.1M |
| 5 |
Eaton
ETN
|
+$15.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$23.5M |
| 2 |
Allstate
ALL
|
+$22.6M |
| 3 |
Cadence Design Systems
CDNS
|
+$21.3M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$20.7M |
| 5 |
Zebra Technologies
ZBRA
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.41% |
| 2 | Consumer Discretionary | 14.8% |
| 3 | Healthcare | 14.63% |
| 4 | Financials | 11.82% |
| 5 | Industrials | 10.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Petrobras
PBR
$118B
| $6K | ﹤0.01% |
+740
| New | +$7.07K |
|
302
AT&T
T
$165B
| $6K | ﹤0.01% |
262
| – | – |
|
303
TG Therapeutics
TGTX
$7.52B
| $6K | ﹤0.01% |
120
-3,390
| -97% | -$163K |
|
|
LMNX
304
DELISTED
Luminex Corp
LMNX
| $6K | ﹤0.01% |
200
-6,000
| -97% | -$178K |
|
305
Emergent Biosolutions
EBS
$229M
| $5K | ﹤0.01% |
50
-1,390
| -97% | -$142K |
|
|
NVTA
306
DELISTED
Invitae Corporation
NVTA
| $5K | ﹤0.01% |
130
-3,900
| -97% | -$177K |
|
|
EGOV
307
DELISTED
NIC Inc
EGOV
| $5K | ﹤0.01% |
140
-4,200
| -97% | -$133K |
|
|
AMED
308
DELISTED
Amedisys
AMED
| $4K | ﹤0.01% |
15
-1,882
| -99% | -$531K |
|
309
CareDx
CDNA
$2.44B
| $4K | ﹤0.01% |
60
-1,590
| -96% | -$123K |
|
310
Insmed
INSM
$29.4B
| $4K | ﹤0.01% |
130
-3,900
| -97% | -$149K |
|
|
BHVN
311
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4K | ﹤0.01% |
60
-1,590
| -96% | -$129K |
|
|
ALLK
312
DELISTED
Allakos
ALLK
| $3K | ﹤0.01% |
30
-930
| -97% | -$117K |
|
|
APLS
313
DELISTED
Apellis Pharmaceuticals
APLS
| $3K | ﹤0.01% |
80
-2,500
| -97% | -$118K |
|
|
KYNB
314
Kyntra Bio
KYNB
$28.2M
| $3K | ﹤0.01% |
3
-92
| -97% | -$98K |
|
|
FOLD
315
DELISTED
Amicus Therapeutics
FOLD
| $3K | ﹤0.01% |
300
-13,148
| -98% | -$204K |
|
316
Ironwood Pharmaceuticals
IRWD
$669M
| $3K | ﹤0.01% |
230
-6,600
| -97% | -$69.7K |
|
317
PTC Therapeutics
PTCT
$6.23B
| $3K | ﹤0.01% |
70
-2,100
| -97% | -$125K |
|
|
RDFN
318
DELISTED
Redfin
RDFN
| $3K | ﹤0.01% |
50
-1,600
| -97% | -$122K |
|
319
Xencor
XNCR
$1.6B
| $3K | ﹤0.01% |
60
-1,700
| -97% | -$80.5K |
|
|
CCXI
320
DELISTED
ChemoCentryx, Inc.
CCXI
| $3K | ﹤0.01% |
60
-1,590
| -96% | -$95.7K |
|
321
Allogene Therapeutics
ALLO
$725M
| $2K | ﹤0.01% |
60
-1,900
| -97% | -$64.1K |
|
322
Heron Therapeutics
HRTX
$63.4M
| $2K | ﹤0.01% |
120
-3,600
| -97% | -$64.2K |
|
323
Inovio Pharmaceuticals
INO
$76.1M
| $2K | ﹤0.01% |
15
-433
| -97% | -$56.9K |
|
324
Regenxbio
RGNX
$688M
| $1K | ﹤0.01% |
40
-1,100
| -96% | -$46.9K |
|
|
ICPT
325
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1K | ﹤0.01% |
30
-1,000
| -97% | -$27.9K |
|
Similar funds
M
GWM
QT
SCM
TW
KFA
SG
FFA
Smith Group Asset Management's Q1 2021 Portfolio in Review
As of Q1 2021, Smith Group Asset Management held 355 positions worth $1.89B, up 9.2% from $1.73B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Smith Group Asset Management's Q1 2021 filing shows 45 new, 117 increased, 138 reduced and 28 closed positions. Its largest new stake was West Pharmaceutical: 84,965 shares worth $24M. The largest sale was Apple, an estimated $23.5M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Smith Group Asset Management's largest Q1 2021 buy was West Pharmaceutical: 84,965 shares worth $24M.
- Smith Group Asset Management added most to Capital One in Q1 2021, an estimated $36.2M increase.
- Smith Group Asset Management's biggest Q1 2021 reduction was Apple, cutting an estimated $23.5M.
- Smith Group Asset Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021, selling an estimated $20.7M.
- Smith Group Asset Management's ten largest holdings make up 34% of its $1.89B portfolio in Q1 2021.
- Smith Group Asset Management opened 45 new positions and closed 28 in Q1 2021.
- Smith Group Asset Management's portfolio value rose 9.2% quarter-over-quarter to $1.89B.
Based on Smith Group Asset Management's 13F filing for Q1 2021, filed 7 May 2021.